LV10308A - Ciliarais neirotropais faktors - Google Patents
Ciliarais neirotropais faktorsInfo
- Publication number
- LV10308A LV10308A LV930441A LV930441A LV10308A LV 10308 A LV10308 A LV 10308A LV 930441 A LV930441 A LV 930441A LV 930441 A LV930441 A LV 930441A LV 10308 A LV10308 A LV 10308A
- Authority
- LV
- Latvia
- Prior art keywords
- cntf
- nucleic acid
- acid sequences
- relates
- variety
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40817289A | 1989-09-15 | 1989-09-15 | |
US42951789A | 1989-10-31 | 1989-10-31 | |
US57065190A | 1990-08-20 | 1990-08-20 | |
PCT/US1990/005241 WO1991004316A2 (en) | 1989-09-15 | 1990-09-14 | Ciliary neurotrophic factor |
Publications (1)
Publication Number | Publication Date |
---|---|
LV10308A true LV10308A (lv) | 1994-10-20 |
Family
ID=27410749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LV930441A LV10308A (lv) | 1989-09-15 | 1993-05-31 | Ciliarais neirotropais faktors |
Country Status (11)
Country | Link |
---|---|
US (1) | US6602687B1 (lv) |
EP (1) | EP0448707B1 (lv) |
JP (2) | JPH05199879A (lv) |
AT (1) | ATE130365T1 (lv) |
AU (1) | AU705371B2 (lv) |
CA (1) | CA2040404A1 (lv) |
DE (1) | DE69023637T2 (lv) |
ES (1) | ES2084045T3 (lv) |
IE (1) | IE903130A1 (lv) |
LV (1) | LV10308A (lv) |
WO (1) | WO1991004316A2 (lv) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141856A (en) * | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
AT405835B (de) * | 1989-01-05 | 1999-11-25 | Synergen Inc | Aufgereinigter ziliärer neurotropher faktor |
IL98304A (en) * | 1990-06-01 | 2008-08-07 | Regeneron Pharma | The ciliary neurotrophic factor receptor |
IT1247150B (it) * | 1991-01-21 | 1994-12-12 | Fidia Spa | Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli. |
RU94016525A (ru) * | 1991-07-10 | 1996-06-10 | Ридженерон Фармасьютикалз | Способы лечения заболеваний двигательных нейронов |
WO1993002206A1 (en) * | 1991-07-23 | 1993-02-04 | Syntex-Synergen Neuroscience Joint Venture | Purification of recombinant ciliary neurotrophic factor and c-terminal truncated ciliary neurotrophic factor and methods for treating peripheral nerve damage |
US5593857A (en) * | 1991-08-23 | 1997-01-14 | Scios Inc. | Production of homogeneous truncated CNTF |
CA2119580A1 (en) * | 1991-10-01 | 1993-04-15 | George Cachianes | Production of gpa neurotrophic factor |
JPH07503128A (ja) * | 1991-11-11 | 1995-04-06 | フィディーア・ソシエタ・ペル・アチオニ | ヒト毛様体ニューロン親和性因子の先端欠失型および突然変異タンパク質型の合成と精製 |
AU4995193A (en) * | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
EP0669987B1 (en) * | 1992-09-25 | 2008-08-13 | Aventis Pharma S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
AU6169894A (en) * | 1993-02-08 | 1994-08-29 | Syntex-Synergen Neuroscience Joint Venture, The | Methods for treating amyotrophic lateral sclerosis with cntf |
WO1994020125A1 (en) * | 1993-03-12 | 1994-09-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5) |
FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
EP0632008B1 (en) | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Pentanoic acid derivatives |
US6143714A (en) * | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
DE69738521T2 (de) | 1996-04-05 | 2009-05-07 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen |
FR2753379B1 (fr) * | 1996-09-13 | 1998-10-30 | Rhone Poulenc Rorer Sa | Methode de traitement de la sclerose laterale amyotrophique |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US6313089B1 (en) | 1997-08-20 | 2001-11-06 | Duke University | Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use |
EP0999270A1 (en) * | 1998-10-09 | 2000-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of regulating SMN gene expression |
JP2003535831A (ja) * | 2000-05-24 | 2003-12-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 毛様体神経栄養因子の使用 |
AU2002358110A1 (en) * | 2001-12-10 | 2003-07-09 | Novartis Ag | Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene |
JP2005073592A (ja) * | 2003-09-01 | 2005-03-24 | Yukiguni Maitake Co Ltd | マイタケ由来のレクチンをコードする遺伝子 |
EP2009103A1 (en) | 2007-03-16 | 2008-12-31 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Neurotrophic peptides |
US8592374B2 (en) | 2007-03-16 | 2013-11-26 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
DK3081637T3 (da) * | 2013-12-11 | 2019-08-12 | Sumitomo Chemical Co | Fremgangsmåde til fremstilling af en ciliær marginalzonelignende struktur |
WO2019246141A1 (en) * | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923696A (en) | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
US4997929A (en) | 1989-01-05 | 1991-03-05 | Synergen, Inc. | Purified ciliary neurotrophic factor |
US5011914A (en) | 1989-01-05 | 1991-04-30 | Collins Franklin D | Purified ciliary neurotrophic factor |
US5141856A (en) | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
CA2047718A1 (en) * | 1989-03-15 | 1990-09-16 | Marston Manthorpe | Purified ciliary neurotrophic factor |
NO911025L (no) * | 1990-03-14 | 1991-09-16 | Fidia Spa | Fremgangsmaate til isolering og ekspresjon av human ciliarneuronotropisk faktor ved rekombinant dna-teknikk. |
-
1990
- 1990-08-29 IE IE313090A patent/IE903130A1/en unknown
- 1990-09-14 EP EP90917018A patent/EP0448707B1/en not_active Expired - Lifetime
- 1990-09-14 JP JP90246008A patent/JPH05199879A/ja active Pending
- 1990-09-14 ES ES90917018T patent/ES2084045T3/es not_active Expired - Lifetime
- 1990-09-14 AU AU67402/90A patent/AU705371B2/en not_active Ceased
- 1990-09-14 AT AT90917018T patent/ATE130365T1/de not_active IP Right Cessation
- 1990-09-14 DE DE69023637T patent/DE69023637T2/de not_active Expired - Fee Related
- 1990-09-14 CA CA002040404A patent/CA2040404A1/en not_active Abandoned
- 1990-09-14 WO PCT/US1990/005241 patent/WO1991004316A2/en active IP Right Grant
-
1992
- 1992-05-08 US US07/883,630 patent/US6602687B1/en not_active Expired - Lifetime
-
1993
- 1993-05-31 LV LV930441A patent/LV10308A/lv unknown
-
2001
- 2001-04-25 JP JP2001128506A patent/JP2001354697A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU705371B2 (en) | 1999-05-20 |
JPH05199879A (ja) | 1993-08-10 |
EP0448707A1 (en) | 1991-10-02 |
ATE130365T1 (de) | 1995-12-15 |
AU6740290A (en) | 1991-04-18 |
DE69023637T2 (de) | 1996-10-17 |
US6602687B1 (en) | 2003-08-05 |
ES2084045T3 (es) | 1996-05-01 |
WO1991004316A2 (en) | 1991-04-04 |
DE69023637D1 (de) | 1995-12-21 |
EP0448707A4 (en) | 1992-11-19 |
CA2040404A1 (en) | 1991-03-16 |
JP2001354697A (ja) | 2001-12-25 |
WO1991004316A3 (en) | 1991-04-18 |
EP0448707B1 (en) | 1995-11-15 |
IE903130A1 (en) | 1991-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV10308A (lv) | Ciliarais neirotropais faktors | |
DE3855921D1 (de) | Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein | |
SI0852585T1 (en) | Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product | |
ATE178616T1 (de) | Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf) | |
DE59003771D1 (de) | Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte. | |
KR920701432A (ko) | 뇌유도성 향신경성 인자 | |
HUP0105027A2 (hu) | N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk | |
ATE256475T1 (de) | Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten | |
GR900100653A (el) | Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο. | |
BG100236A (en) | Sheared keratiocytic growth factor (kgf) of increased biological activity | |
DE3584120D1 (de) | Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
ATE17858T1 (de) | Angiotropine aus leukozyten und entzuendeten geweben: eine neue klasse von natuerlichen chemotropischen und mitogenen proteinen fuer die spezifische induktion des gesteuerten wachstums von blutgefaessen, fuer neue gefaessbildung von geweben und fuer die morphogenese von blutgefaessverzweigungen; verfahren zu ihrer biotechnischen herstellung und pharmazeutische zusammensetzungen. | |
EP0458673B1 (en) | Growth-inhibitory factor and cDNA coding for growth inhibitory factor | |
DE19681032D2 (de) | Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen | |
GR900100691A (el) | Νευροτροφικός παράγοντας ακτινωτού. | |
PT990000E (pt) | Factor 3 de crescimento do tecido conjuntivo | |
JPH05125097A (ja) | 神経細胞およびグリア細胞に作用する新規タンパクおよびそれを含有する医薬品 |